Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Bevacizumab and CapeOX in LACRC
NCT06550453Phase 4Recruiting
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pembrolizumab in rectal cancer. Started Sep 2024; status: recruiting.
02
Drugs
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06550453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550453.